Acquisition of Multi-PI (Protease Inhibitor) Resistance in HIV-1 In Vivo and In Vitro

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|10|32|4055-4064

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.10, Iss.32, 2004-12, pp. : 4055-4064

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Resistance to the HIV Protease Inhibitor Amprenavir In Vitro and in Clinical Studies: A Review

By Tisdale M.   Myers R.   Randall S.   Maguire M.   Ait-Khaled M.   Elston R.   Snowden W.  

Clinical Drug Investigation, Vol. 20, Iss. 4, 2000-10 ,pp. : 267-285

Adis International

Access to resources Recommend Favorite

Tipranavir: a protease inhibitor for multi-drug resistant HIV-1

By Best Brookie   Haubrich Richard  

Expert Opinion on Investigational Drugs, Vol. 15, Iss. 1, 2006-01 ,pp. : 59-70

Informa Healthcare

Access to resources Recommend Favorite

Replacing a protease inhibitor (PI) with nevirapine is feasible in HIV infections

By  

Inpharma, Vol. 1, Iss. 1493, 2005-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Structural and Thermodynamic Basis of Resistance to HIV-1 Protease Inhibition: Implications for Inhibitor Design

By  

Current Drug Targets - Infectious Disorders, Vol. 3, Iss. 4, 2003-12 ,pp. : 311-328

Bentham Science Publishers

Access to resources Recommend Favorite

Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment

By Barragan Patricia   Podzamczer Daniel  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 13, 2008-09 ,pp. : 2363-2375

Informa Healthcare

Access to resources Recommend Favorite